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 Acute renal failure (ARF) is a sudden 
loss of the kidneys ’ excretory function 
occurring within hours or days after 
an abrupt renal insult. ARF still poses a 
major human, clinical, and socioeconomic 
burden whose incidence and mortality 
have remained considerably high during 
the past 60 years in spite of the improve-
ment of dialysis and acute-care tech-
niques. 1 The etiopathology of ARF is 
usually multifactorial, although incom-
pletely understood. Causes are oft en clas-
sified into (1) prerenal, due to an 
inadequate blood supply (as in hypoten-
sion or arterial obstruction); (2) intrinsic, 
due to functional or structural alterations 
of the renal parenchyma (for example, 
drug-induced nephrotoxicity); and (3) 
postrenal, caused by impairment of urine 
output (for example, ureteral obstruction 
or prostate enlargement). Among them, 
ischemia and nephrotoxicity are the most 
common triggers of ARF in the clinical 
setting. Ischemic ARF is oft en caused by 
hypotension, renal artery thrombosis, or 
surgical clamping of the aorta or the renal 
arteries. In high-risk patients subjected to 
this type of surgery, the incidence of 
ischemic renal dysfunction has been 
reported to be as high as 50 % . 2 An exem-
plifying case of nephrotoxicity is posed by 
cisplatin, a chemotherapeutic drug widely 
used for the treatment of diverse solid 
tumors. Its nephrotoxicity is, however, a 
serious and limiting side effect that 
requires both dosage lowering and patient 
hydration. Despite this, ARF still occurs 
even at low doses and especially upon 
repeated administration. 3 
 In the context of ARF, renal tubular cells 
(RTCs) are damaged, resulting in acute 
tubular necrosis. RTCs are epithelial cells 
highly specialized in the effi  cient trans-
cellular transport of water, electrolytes, 
and macromolecules through highly 
selective, tightly regulated, and adenosine 
triphosphate (ATP)-consuming trans-
porters. ATP availability is thus a critical 
aspect of RTC homeostasis. ATP decline 
occurring during acute renal dam-
age disrupts transport mechanisms, 
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 Potential utility of PPAR  
activation in the prevention of 
ischemic and drug-induced 
acute renal damage 
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 Acute renal failure induced by renal ischemia or drugs continues to be 
a relevant clinical problem. Li  et al. have demonstrated that proximal 
tubule-restricted peroxisome proliferator–activated receptor-  (PPAR  ) 
expression in transgenic mice reduced cisplatin- and ischemia /
 reperfusion-induced acute renal injury. Their article suggests a role for 
the maintenance of free fatty acid oxidation in the proximal tubule 
as a mechanism of nephroprotection, as well as a potential clinical utility 
of PPAR  activators in the prevention of acute renal failure. 
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including the basolateral Na   +   K   +   ATPase 
pump, which leads to intracellular Na   +  
and water accumulation, swelling, dis-
ruption, and eventually cell death. 1 In 
ischemic ARF, ATP synthesis falls as a 
consequence of diminished oxygen sup-
ply. Yet an additional injury occurs upon 
kidney reperfusion, which is mediated 
by oxidative stress generated by (1) 
an increased production of reactive 
oxygen species, (2) deregulation of 
calcium homeostasis, (3) phospholipase 
and protease activation, (4) cellular 
pH alteration, and (5) infiltration of 
 infl ammatory cells. 4 In cisplatin nephro-
toxicity, ATP synthesis decreases as a result 
of mitochondrial dysfunction, increased 
oxidative stress, and infl ammation. 4 
 Fatty acid oxidation (FAO) provides a 
major source of ATP in proximal RTCs. 
Among other modulators, FAO is regu-
lated by peroxisome proliferator-
activated receptors (PPARs), a group of 
transcription factors belonging to the lig-
and-activated nuclear hormone receptor 
superfamily. PPARs have been shown to 
control many biological processes, 
including (1) energy homeostasis, and 
lipid and glucose metabolism through 
FAO, gluconeogenesis, and stimulation 
of ketone body synthesis; (2) adipogen-
esis; (3) inhibition of the immune 
response; and (4) cell growth and diff er-
entiation. 5 
 PPARs form heterodimers with retinoid X 
receptors. Th ese complexes regulate tran-
scription by binding to PPAR response 
elements in the promoter region of target 
genes, including those encoding mito-
chondrial and peroxisomal FAO enzymes, 
and mediators of cellular fatty acid import 
( Figure 1 ). 6 Th ree subtypes of PPARs have 
been described, namely PPAR  , PPAR  /  , 
and PPAR  . PPAR  is predominantly 
expressed in metabolically active organs 
and tissues, such as the liver, the heart, 
skeletal muscle, brown fat, and renal proxi-
mal tubule cells. Th e main physiological 
activators of PPARs are fatty acid metabo-
lites primarily derived from arachidonic 
or linoleic acids through the cyclooxy-
genase or the lipoxygenase pathways. Th e 
best-characterized PPAR  activators are 
leukotriene B4 (LTB4) and hydroxyeico-
satetraenoic acid (8S-HETE) ( Figure 1 ). 
 Increasing evidence supports a role 
for PPAR  in the development of ARF. Sev-
eral groups have demonstrated that, in 
renal tissue from rats and mice undergoing 
cisplatin- and ischemia / reperfusion (I / R)-
induced ARF, there is a reduction of PPAR  
expression and transcriptional activity, and 
inhibition of peroxisomal and mitochon-
drial FAO enzymes. 7 Failure to oxidize fatty 
acids and long-chain acylcarnitines results 
in their accumulation and cellular toxicity, 
which further contributes to proximal 
tubule cell death. 7 It is of note that PPAR  
and FAO inhibition during ARF is not due 
to a reduced availability of arachidonic and 
linoleic acids, which are otherwise 
increased during ARF following the 
enhanced activity of phospho lipases A2 
and C ( Figure 1 ). 8 It has also been reported 
that activation of PPAR  with ligands such 
as fi brate or WY14643 reduces cisplatin- 
and I / R-induced acute kidney injury; 9 pre-
vents FAO inhibition and nonesterifi ed fatty 
acid and tri glyceride accumulation in kid-
ney tissue; and reduces proximal tubule cell 
apoptosis and necrosis, resulting in a sig-
nificant protection of renal function. 
Importantly, these eff ects of fi brate and 
WY14643 are not observed in PPAR  -null 
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 Figure 1  |  Schematic representation of signaling pathways involving PPAR  that are  
 implicated in the pathophysiological mechanisms of ischemic and drug-induced acute 
renal damage. PPAR  dimerizes with retinoid X receptors. In the presence of PPAR  ligands, such 
as fatty acid oxidation products (leukotriene B4 (LTB4), hydroxyeicosatetraenoic acid (8S-HETE), 
and so on), the dimer ligates a coactivator molecule, binds to peroxisome proliferator response 
elements in the promoter region of target genes, and activates their transcription. This leads 
to an increase in fatty acid catabolism and adenosine triphosphate production, to a decrease 
in the levels of cytotoxic fatty acid peroxidation products, and, consequently, to promotion of 
cell viability and inhibition of cell death. In the ligand-free form, the PPAR  – retinoid X receptor 
heterodimer recruits a nuclear corepressor and represses the expression of PPAR  target genes. 
During acute renal damage, PPAR  is ubiquitinated and degraded, which compromises cell 
viability and activates the cell death processes. ATP, adenosine triphosphate; CoAct, coactivator; 
CTK, cytokine; FAO, fatty acid oxidation; FFA, free fatty acid; GF, growth factor; H, hormone; 
NCoR, nuclear corepressor; NF-  B, nuclear factor-  B; PPAR α ,  peroxisome proliferator-activated 
receptor- α ; POx, peroxidation; RXR, retinoid X receptor. 
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mice. 9 Altogether, these observations 
strongly endorse a critical role for PPAR  
in promoting FAO in the kidneys that 
closely correlates with preservation of renal 
morphology and function during cisplatin- 
and I / R-induced acute renal damage. 
 Li  et al. 10 (this issue) further investigate 
the role of PPAR  in cisplatin- or I / R-
induced ARF, by using a transgenic 
mouse model that expresses the mouse 
PPAR  under the control of the kidney 
androgen–induced protein 2 (KAP2) pro-
moter. KAP2 is exclusively expressed in 
proximal tubules under the control of 
androgens, which consequently restricts 
the expression of this transgene to the 
proximal tubule compartment. In this 
study, PPAR  expression was induced by 
testosterone in proximal tubules of female 
KAP2-PPAR  transgenic mice. Th is man-
euver aff orded protection against cispla-
tin- and I / R-induced inhibition of FAO 
and protected kidney function and 
morpho logy from these insults, in com-
parison with their eff ect on wild-type mice. 
Along with the studies of Nagothu  et al. 9 
with PPAR  -null mice, the approach of 
Li  et al. 10 further corroborates the essen-
tial involvement of PPAR  in the renal 
protection provided by PPAR  activators, 
which further rules out potential PPAR  -
independent, renoprotective actions of 
PPAR  activators. Th e conditional and 
proximal tubule-restricted expression 
model of Li  et al. 10 steps further by dis-
carding potential PPAR  -mediated, extra-
renal eff ects that might be responsible for 
the renal protection aff orded by PPAR  
activators in the PPAR  -null mouse. 
 Th is study highlights the importance of 
maintaining FAO to protect the kidney 
against acute injury. On the one hand, 
mouse kidney cortex cells utilize poly-
unsaturated fatty acids as a major source 
of energy production. On the other hand, 
by catabolizing lipids for ATP production, 
FAO prevents their peroxidation, which 
leads to the formation of cytotoxic 
lipid-aldehyde species such as 4-hydroxy-
2-nonenal (4-HNE) and 4-hydroxy-2-hex-
enal (4-HHE). Indeed, previous studies 
have documented an increased formation 
of 4-HHE in kidney tissue aft er I / R injury. 11 
4-HHE can cause mitochondrial dysfunc-
tion and cell death by (1) enhancing calcium-
mediated induction of mitochondrial 
permeability; (2) inhibiting the mitochon-
drial ATP translocator; (3) inducing Bax 
and reducing Bcl-2 expression; and (4) 
stimulating the inducible nitric oxide syn-
thase in the endothelium through nuclear 
factor-  B activation, which produces vas-
cular infl ammatory dysfunction. 12 
 Li  et al. 10 show data indicating that the 
increased level of 4-HHE (or HHE-modi-
fi ed protein) induced by I / R and cisplatin 
in renal tissue is signifi cantly inhibited in 
KAP2-PPAR  transgenic mice treated 
with testosterone, which induces PPAR  . 
Th e increased and targeted expression of 
PPAR  reduces the formation of 4-HHE 
in the proximal tubule. It also suggests 
that 4-HHE might mediate pathophysi-
ological proximal tubule cell death trig-
gered by oxidative stress.  Other 
PPAR  -mediated mechanisms potentially 
involved in renal protection might be 
based on the increased expression of 
genes controlling mitochondrial biogen-
esis and function, such as those associated 
with oxidative phosphorylation (com-
plexes I – V), mitochondrial DNA replica-
tion and repair, fatty acid metabolism, 
and the tricarboxylic acid cycle. Th ese 
fi ndings corroborate previous observa-
tions on the participation of PPAR  in 
these processes, in mice treated with 
fi brate. 13 It is important to emphasize that 
either forced increased expression of 
PPAR  (resulting in increased levels of 
this receptor) or its activation with lig-
ands is independently capable of enhanc-
ing PPAR  -mediated transcriptional 
activity, and of aff ording renal protection. 
Th is implies that, during ARF, (1) there 
seems to be some reasonable margin for 
PPAR  activation (that is, with exogenous 
ligands) in spite of reduced levels of this 
protein, which suggests that, apparently, 
the amount of endogenous activators is 
limited, or, in other words, the level of 
PPAR  is still in excess for the level of 
activators; and (2) accordingly, it is diffi  -
cult to understand how, in these circum-
stances, a forced overexpression of PPAR  
translates into a higher transcriptional 
activity. Clearly, further knowledge is 
necessary. 
 Th e results from the article of Li  et al. 10 
demonstrate that the increased expression 
or activity of PPAR  prevents, or at least 
softens, the renal damage and lipid 
 meta bolism abnormalities associated with 
cisplatin- or I / R-induced ARF. Th ey also 
reinforce the potential clinical utility 
of PPAR  activators in the prevention 
of ARF. A role for FAO maintenance in the 
proximal tubule as a mechanism of nephro-
protection is suggested by these experi-
ments. However, further investigation is 
necessary to more deeply ascertain the 
specifi c roles and relative weight of FAO, 
ATP pool conservation, and the eff ect of 
the inhibition of peroxidation products in 
the overall renal injury observed upon I / R 
or drug administration. 
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